The new AUC document was designed to help care teams know when and how to perform imaging-based cardiovascular evaluations on patients undergoing nonemergent, noncardiac surgery.

Researchers hoped to gain a better understanding of the device's real-world impact by reviewing registry data from more than 97,000 U.S. patients. Overall, the Watchman FLX was linked to positive data and limited adverse events one year after treatment. 

The American College of Cardiology, American Heart Association and Heart Failure Society of America worked together on the updated document, adding three new performance measures and six new quality measures. They did not remove a single recommendation from the previous document published in 2020.

Using a cerebral protection device during TAVR was associated with lower readmission rates, shorter hospital stays—and, yes, a lower risk of patients suffering a major stroke. A team of specialists with Cleveland Clinic shared their new findings in the Journal of the American Heart Association.

Bharath Krishnamurthy, a director of health policy and analytics at the American Hospital Association, explains the financial impact of current healthcare staffing shortages.

Individuals are 83% more likely to be diagnosed with a psychiatric disorder within one year of a CVD hospitalization, according to new data published in the Journal of the American Heart Association.

The new PREVENT CVD risk calculator could result in more than 16 million heart patients who are no longer eligible for preventive therapy. These significant changes “carry the potential for both benefit and harm," researchers wrote in JAMA.

New one-year data suggests transseptal MViV with a Sapien 3 heart valve is a "favorable and safe procedure." Researchers plan to follow patients for a total of 10 years.